VERA NASDAQ
Vera Therapeutics, Inc.
1W: -4.9%
1M: -13.1%
3M: -6.7%
YTD: -27.6%
1Y: +60.8%
3Y: +107.4%
5Y: +120.2%
$33.32
-1.86 (-5.29%)
Weekly Expected Move ±7.4%
$30
$33
$35
$38
$41
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.4B
52W Range19.066-56.05
Volume2,193,423
Avg Volume1,649,055
Beta0.92
Dividend—
Analyst Ratings
Company Info
CEOMarshall Fordyce
Employees249
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-14
Websiteveratx.com
8000 Marina Boulevard
Brisbane, CA 94005
US
Brisbane, CA 94005
US
650 770 0077
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Latest News
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Moderate Buy” by Brokerages
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Is Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?
Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings
3 Biotech Firms With Major Potential Catalysts in the Coming Months
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fordyce Marshall | S-Sale | 1,000 | $40.78 | 2026-07-07 |
| Fordyce Marshall | S-Sale | 32,550 | $42.07 | 2026-07-07 |
| Fordyce Marshall | S-Sale | 10,500 | $42.86 | 2026-07-07 |
| Fordyce Marshall | S-Sale | 2,200 | $43.59 | 2026-07-07 |
| Fordyce Marshall | S-Sale | 18,412 | $37.93 | 2026-06-23 |